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Abstract: Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinson’s disease. It is 
generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the 
progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been 
shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinson’s disease models. 
Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine 
agonists currently used for treating Parkinson’s disease patients. In particular, the mechanism of action of different 
dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since 
at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective 
activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and 
progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a 
primary role.  
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1. INTRODUCTION 
 Parkinson’s disease (PD), Parkinson's disease with 
dementia (PDD), Lewy bodies dementia (DLB) and 
Alzheimer’s disease (AD) are a heterogeneous group of 
neurodegenerative disorders characterized by gradually 
progressive, selective loss of anatomically or functionally 
related neuronal systems. Although it is not clear whether or 
not these diseases represent part of the same disease 
spectrum, they share common clinical phenomenology and 
pathological substrate but differ in spatial and temporal 
evolution of the disease process. Age appears to have a 
significant, if not dominant, effect in modifying disease 
expression within this spectrum. Despite this heterogeneity, 
neuronal cell loss is perhaps the most important common 
theme in these diseases. Thus, the development of disease-
modifying therapeutic strategies that combine both symp-
tomatic and neuroprotective effects is definitely required for 
effective management of these diseases. 
 PD is the most common neurodegenerative movement 
disorder. Approximately 2% of the population older than 65 
years suffers from this slowly progressive neurodegenerative 
disease. More than 90% of PD cases are sporadic. The 
primary cause of the disorder is the progressive loss of the 
pigmentated DAergic neurons in the substantia nigra pars 
compacta (SNpc) accompanied by the appearance of 
intracytoplasmic inclusions known as Lewy bodies. Lewy 
bodies contain aggregated alpha synuclein. Interestingly, 
patients with abnormalities in the Parkin gene have a 
recessive, early onset Parkinsonism and do not have Lewy 
bodies. In contrast patients with dominant forms of  
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hereditary PD and patients with idiopathic PD do have Lewy 
bodies [1]. As the disorder progresses, neurodegenerative 
changes and Lewy bodies are seen in other parts of the brain, 
including the cranial nerve nuclei, the nucleus basalis, locus 
coeruleus, and specific nuclei of the hypothalamus. 
 Many patients with PD develop dementia. In addition 
there is a type of dementia known as LBD in which Lewy 
bodies are found not only in the areas which contain 
neuromelanin, like the SN, but in numerous other areas 
including temporal lobe and cingulate gyrus. In the latter 
locations they are not as well demarcated or as distinct as the 
typical Lewy bodies. However, like all Lewy bodies, they 
can be stained with antibodies against ubiquitin [1, 2]. This 
makes them much easier to be detected and this test should 
be performed in any case of dementia where histology has 
ruled out AD and in which typical Lewy bodies have been 
recognized in SN or locus coeruleus. The relationship 
between PDD and LBD is a matter of some controversies. 
Moreover, cases that appear to have both AD and LBD have 
been reported and in these cases the burden of senile plaques 
and neurofibrillary tangles is less than that normally seen 
with dementia of the pure Alzheimer type. Amyloid plaques 
in sporadic LBD and AD show an identical biochemistry and 
progression pattern, suggesting a metabolic defect of amy-
loid precursor protein as a risk factor for synucleinopathy.  
 To date, the etiopathogenesis of nigral DAergic neuron 
loss in PD is unknown. However, the presence of ongoing 
oxidative stress as the result of inefficacious antioxidant 
defence mechanisms and generation of radical oxygen 
species (ROS) in the SNpc of the parkinsonian brain are 
considered to be important pathogenic mechanisms [3-5]. It 
should be noted that part of these free radicals are inevitably 
produced by DA metabolism in the brain either by enzymes 
through the action of monoamine oxidase-B or by auto-
oxidation [6]. Other sources of increased radical production 
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may be endogenous neurotoxins occurring in the brain like 
tetrahydroisoquinolines or exogenously administered neuro-
toxins like the widely used herbicide paraquat which have 
similar neurochemical properties like the well-known 
neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) [7-9]. Moreover, it has been suggested that PD 
could be associated with excitotoxicity and apoptosis [10]. 
Therefore, an effective anti-parkinson therapy should not 
only alleviate the disease associated symptoms, but should 
also interfere with the progressive DAergic death in the SN.  
 Levodopa combined with a peripheral DOPA-decar-
boxylase inhibitor and a COMT inhibitor is considered the 
therapy of choice for PD. Levodopa is nearly always 
effective, but has a high incidence of adverse effects with 
long term use, including response fluctuations (on/off 
phenomena) and dyskinesias. DAergic agonists, acting 
directly at the receptor level, would be able to decrease the 
incidence of these motor complications. In the last 2 years, 
three new DA agonists have been launched, including 
ropinirole, pramipexole and cabergoline. These new agonists 
have been added as therapeutical options to well-established 
drugs, like pergolide, bromocriptine or talipexole [4, 5].  
 Here we review recent data underlining the potential 
pleiotrophic effects of some of the DA agonists currently 
used for the treatment of PD. The wide and molecule-
specific pharmacological spectrum of these drugs may 
participate in restoring the impaired DA function by stimu-
lating DA D2 receptors as well as in preventing neuro-
degenerative processes by additional pharmacological 
properties. 
NOVEL PHARMACOLOGICAL PROPERTIES OF DA 
AGONISTS 
 The rationale for using DA agonists in the treatment of 
motor disturbances present in PD stands on the capability of 
these drugs to restore the striatal DAergic imput that is 
impaired in PD. We argue that, besides these pharmaco-
logical effects, DA agonists may inhibit intracellular death 
pathways and/or stimulate neuron regeneration. These effects 
may be a consequence of (specific) DA receptor stimulation 
or be completely independent from them. These additional 
pharmacological effects may also involve sites of action 
distal from the nigro-striatal areas and contribute to slow 
down the progression of the neurodegenerative process. We 
have selected four potential pharmacological effects that 
alone or in combination may enlarge the pharmacological 
spectrum of different DA agonists. 
Antioxidant Activity 
 In progressive neurodegenerative diseases, such as PD, 
modification of the rate of disease progression is currently a 
highly debated topic. Increased oxidative stress is thought to 
be involved in nigral cell death, that is characteristic of PD. 
This oxidative stress may be further exacerbated by levodopa 
therapy. These mechanisms have been proven in vitro and in 
animal models, but their relevance in humans remains 
speculative [4, 5]. Based on these considerations, the 
emerging therapeutic strategies for PD advocate early use of 
DA agonists in the treatment of PD. A number of recent 
well-controlled studies have proven the efficacy of DA 
agonists used as monotherapy. Moreover, as predicted by 
animal studies, on the long term, DAergic agonists induce 
significantly less motor complications than levodopa.  
 It is generally believed that treatment with DAergic drugs 
is symptomatic rather than curative and it does not stop or 
delay the progression of neuronal degeneration. However, 
several DA agonists of the D2-receptor family (including D2 
and D3 subtypes) have recently been shown to possess 
neuroprotective properties in different in vitro and in vivo 
experimental PD models. Most DA agonists have demons-
trated protective properties in cell culture against a range of 
toxins, including DA, 6-hydroxydopamine (6-OH-DA), 1-
methyl-4-phenylpyridinium (MPP
+
) and hydroxy peroxide 
[4, 5, 11]. DA agonists also protect against toxin action in 
vivo, as shown in rodents receiving intrastriatal injection of 
6-OH-DA or MPP
+
. As reported in details in the following 
chapters, at cellular level, independent groups have demons-
trated decreased free radical production and an amelioration 
of DA neuronal loss following DA agonist treatment.  
Stimulation of Neurogenesis 
 The neurotransmitter and its receptors appear early 
during ontogenesis and affect cell proliferation in the emb-
ryonic germinal zones [12, 13]. Interestingly, the regulation 
of neural stem cells by DA persists in the restricted brain 
areas where neurogenesis occurs in adulthood, particularly in 
the subventricular zone (SVZ) within the lateral wall of the 
lateral ventricles and in the subgranular zone of the 
hippocampus. Ongoing adult neurogenesis is currently 
believed to be an important form of neural plasticity, 
enabling organisms to adapt to environmental changes and 
possibly influencing learning and memory throughout life. 
On the other hand promotion of adult neurogenesis may offer 
a potential approach for replacing neurons or neuritic 
networks that degenerate or lose function during aging or in 
neuropathological settings, including PD. This therapeuthic 
strategy is particularly intriguing since in post-mortem brains 
of individuals with PD the numbers of neural precursor cells 
in neurogenic regions are dramatically reduced [14]. In a 
very elegant study Hoglinger and coauthors [14] provided 
experimental evidences that the highly proliferative 
precursors cells located in the adult murine subependymal 
zone lining the lateral ventricle receive dopaminergic 
afferents. This innervation appears functionally relevant. 
Transient and bilateral dopaminergic denervation by 
administration of MPTP resulted in transient and bilateral 
decrease in the subependymal zone proliferation. 
Additionally, ablation of mesencephalic dopaminergic 
neurons of adult rats by stereotaxic injection of 6-OHDA 
into the nigrostriatal pathway resulted in the unilateral 
dopaminergic denervation of the subependymal zone as well 
as in the marked reduction in the number of proliferating 
precursors. Conversely, cell proliferation was restored by L-
DOPA chronic infusion. Similar results were obtained in the 
hippocampal neurogenic region, which has been shown to 
receive a dopaminergic from the ventral tegmental area. 
More recently, the existence of a topographically organized 
projection from the SNpc to the SVZ was also demonstrated 
in primates [15], with the anteromedial SNpc projecting to 
the anteroventral SVZ and the posterolateral SNpc to the 
posterodorsal SVZ. 
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 The effects on precursor cell proliferation elicited by 
dopamine are likely to be mediated by D2-like receptors, 
since D2 and D3 receptors are expressed on neural 
stem/progenitors cells. As recently summarized by Joyce and 
Millan [16], different D3 receptor-preferring agonists 
augment mitogenesis in the SVZ. In particular, Van Kapen 
and associates demonstrated induction of neurogenesis 
leading to the regeneration of DAergic pathways, suggesting 
that this effect may participate in the restoration of DAergic 
nigrostriatal pathway and locomotor activity in a rat model 
of PD [17, 18]. However, species-specific differences of D3 
receptors in regulating neurogenesis have been reported [19, 
20]. A two-fold induction of cell proliferation in the SVZ 
and rostral migratory stream of the adult rats was demons-
trated following icv administration of the dopamine D(3) 
receptor agonist, 7-hydroxy-N,N-di-n-propyl-2-aminotetralin 
(7-OH-DPAT) for 2 weeks [17]. The same drug had no 
effect on mice [20, 21]. More robust are the data on the 
involvement of D2 receptors in regulating neurogenesis, 
based on both the use of D2-null mice and D2 agonists/ 
antagonists [22].  
 Whether or not reduced neurogenesis may be a cones-
quence of or rather contribute to the pathophysiology of PD 
certainly deserves further investigation since these studies 
may have significant implications for the future design of 
novel therapeutic strategies. 
Anti-Fibrillary Activity 
 Very recent data suggest anti-fibrillary effects of DA 
agonists. The aggregation of -amyloid peptide (A) and 
alpha-synuclein in the brain has been implicated as a critical 
step in the development of AD and LBD, respectively. Thus, 
in addition to antioxidant strategies, increasing evidence 
points to the possibility of achieving neuroprotection by DA 
agonists through inhibition of fibril formation [23]. DAergic 
agents were indeed found to dose-dependently inhibit 
generation of, as well as destabilize preformed, -amyloid 
fibrils [24]. Using fluorescence spectroscopy with thioflavin 
S, electron microscopy, and atomic force microscopy, the 
effects of selegiline, DA, pergolide, bromocriptine, and 
trihexyphenidyl on alpha-synuclein fibrils formation have 
been recently studied. All molecules, except for trihexy-
phenidyl, dose-dependently inhibited the formation of alpha-
synuclein fibrils. Moreover, these molecules dose-depen-
dently destabilized preformed alpha-synuclein fibrils [25]. 
The anti-fibrillary actions elicited by the DA agonists appear 
to be independent of DA receptor stimulation and detectable 
in cell-free systems.  
Stimulation of Neurotrophic Factors 
 One of the most convincing evidence for the role of 
neurotrophic factors in PD is the very recent study of 
Elsworth et al. [26]. They found that implantation of adeno-
associated virus type 2 encoding glial derived neurotrophic 
factor (AAV2-GDNF) in the normal monkey caudate 
nucleus induced overexpression of GDNF that persisted for 
at least 6 months after injection. In a 6-month within-animal 
con-trolled study, AAV2-GDNF enhanced the survival of 
fetal dopamine neurons by 4-fold, and increased the 
outgrowth of grafted fetal dopamine neurons by almost 3-
fold in the caudate nucleus of MPTP-treated monkeys, 
compared with control grafts in the controlateral caudate 
nucleus. GDNF is a potent neurotrophic factor that is crucial 
for development, survival, and outgrowth of DA neurons 
[27, 28]. GDNF is highly expressed in the developing rat 
striatum, yet its concentration is relatively low in the adult 
brain [29-31]. Several studies in the 6-OH-DA lesioned 
striatum of rats have demonstrated improvements in survival 
and outgrowth of grafted fetal DA neurons when SNC 
injections of GDNF have been administered, or when GDNF 
overexpressing cells have been co-grafted to the striatum 
[32-38].  
 Other than GDNF, brain-derived neurotrophic factor 
(BDNF) is one of the major trophic factors for DAergic 
neurons [39-41]. Transplantation of modified fibroblasts or 
astrocytes that express BDNF into either the striatum or the 
midbrain attenuates 6-OH-DA-induced loss of nigrostriatal 
neurons [42-43]. Also, BDNF can modulate dopaminergic 
neurotransmission in nigrostriatal neurons, as shown by 
elevated rotational behavior and increased turnover of 
dopamine in the striatum [39]. BDNF can promote functional 
recovery from 6-OHDA lesions following expression in 
striatal cells from an AAV vector [44]. 
 These studies support the relevance of neurotrophic 
factors for a neurorestorative effect expected in the treatment 
of PD. As reported in the following chapters, some DA 
agonists have been found to stimulate either BDNF or 
GDNF in experimental cell cultures. These pharmacological 
effects may be useful to improve treatment for PD. 
2. EXPERIMENTAL EVIDENCE FOR NEURO-
RESCUE ACTIVITY 
Apomorphine 
 Apomorphine, a non-ergoline DA receptor agonist, is a 
short-acting and non-selective DA D1/D2 receptor agonist 
used for treating PD since many decades. Subcutaneous 
intermittent injections or continuous infusions of apomor-
phine have been proposed for the management of sudden, 
unexpected and refractory levodopa-induced “off” states in 
fluctuating PD [45].  
 The original evidence for neuroprotective and antioxidant 
effects of apomorphine, and other DA receptor agonists, is 
from Youdim’s group [46]. Rationale for their pivotal studies 
was the relevance of ROS generation in the neurotoxicity 
associated with PD [3, 6]. Since compounds with a catechol 
structure have metal chelating properties and can act as 
reducing agents [47], it was attractive that apomorphine may 
inhibit metal-catalyzed free radical processes and act as a 
free radical scavenger. Studies on the effect of apomorphine 
on lipid peroxidation and protein carbonyl formation after 
ascorbate/iron-induced free radical formation in rat brain 
mitochondrial fractions clearly demonstrated the antioxidant 
properties of apomorphine in brain tissue [46, 48].  
 It has later been shown that apomorphine exhibited 
neuroprotection against DA depletion in 6-OH-DA lesioned-
rats [49] and MPTP-treated mice [50]. Furthermore, 
continuous subcutaneous infusion of apomorphine was found 
to rescue striatal DAergic terminals and increase the tyrosine 
hydroxylase and DA-transporter immunoreactivity against 
toxicity induced by MPTP in mice and enhanced the number 
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of tyrosine hydroxylase-positive cells in the ventral 
tegmental area in partially 6-OH-DA-lesioned rats [51, 52]. 
It has also been observed that apomorphine increased the 
survival of cultured mesencephalic DAergic cells [53] 
suggesting trophic effects of apomorphine either in vivo or in 
vitro. The neuroprotective effect of apomorphine was further 
supported by the result of different pharmacological properties 
including antioxidant activity, potent iron chelating action, 
inhibition of lipid peroxidation, induction of neurotrophic 
factors and anti-inflammatory effects [46, 50, 54-56]. 
 Recently, specific brain gene expression changes have 
been reported in the chronic MPTP model in the late stage of 
degeneration, employing cDNA expression array, which 
indicating a domino cascade of events involved in neuronal 
cell death [57]. Specifically, the authors detected alterations 
in the expression of genes implicated in oxidative-stress, 
inflam-matory processes, signal transduction and glutamate 
toxicity. Induction of these pro-toxic genes appeared to be 
prevented in mice pretreated with apomorphine.  
Bromocryptine and Quinpirole 
 Bromocryptine is the first DA receptor agonist that has 
been approved for anti-parkinsonian therapy since 1974 [58]. 
It was first used as adjunctive therapy to levodopa in patients 
experiencing motor fluctuations and later it was recom-
mended as monotherapy in the early stage of the disease 
[59]. From a pharmacological point of view, bromo-cryptine 
was the first DA receptor agonist endowed with D2 receptor 
specificity to be described. Bromocryptine has been shown 
to protect mice and DAergic cells against 6-OH-DA and 
MPTP, and levodopa-induced cell loss, respectively; it also 
attenuated DA depletion in mouse striatum in response to 
methamphetamine [60-62]. The neuroprotective effect of 
bromocryptine was dependent on both its action as a D2 
receptor agonist and its antioxidant capacity. In this context, 
it has been reported that bromocryptine is able to scavenge 
hydroxyl and superoxide radicals in vitro [61, 63] and to 
inhibit hydroxyl radical formation and lipid peroxidation in 
vivo [61]. 
 Glutamate, the main excitatory neurotransmitter in the 
mammalian brain, contributes to the neuronal death 
associated with neurodegenerative diseases, such as AD and 
PD, and with ischemia. Bromocryptine has been shown to 
exert a protective effect against glutamate-induced cytoto-
xicity in primary cultures of rat cortical or mesencephalic 
neurons [64] The neuroprotective effect was mediated via 
D2 receptors, because it was attenuated by domperidone, a 
D2 DAergic receptor antagonist. Another DA D2 agonist, 
quinpirole, also protected cells against glutamate toxicity. In 
particular, the D2 agonists protected cells from calcium 
influx, nitric oxide, and peroxynitrite toxicity, which are 
thought to be the mediators of glutamate toxicity. The 
phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002 
inhibited this neuroprotective effect of bromocriptine. 
Furthermore, Akt protein kinase, which is an effector of 
PI3K, was activated by bromocriptine, and the antiapoptotic 
protein Bcl-2 was up-regulated by bromocriptine treatment. 
These results suggested that D2 DAergic receptor activation 
plays an important role in neuroprotection against glutamate 
cytotoxicity and that the up-regulation of Bcl-2 expression 
via the PI3K cascade is, at least partially, involved in this 
effect. 
 Recently, Marvanova and Nichols [65] investigated 
mechanisms of PD in Caenorhabditis elegans (C. elegans). In 
general, striking and profound similarities underlie the basic 
cellular and molecular processes between the worm and 
humans. The use of C. elegans over traditional mammalian-
based systems holds the promise of an enhanced rate of 
discovery with lower associated costs. In particular, they 
utilized C. elegans to screen a variety of compounds, 
including specific DA receptor agonists, such as bromo-
criptine and quinpirole, to identify those that protect against 
6-OH-DA-induced DAergic toxicity. The two DA D2 
receptor agonists were found to protect against 6-OH-DA 
toxicity in a dose-dependent manner. Surprisingly, these 
protective effects appear to involve receptor-independent 
mechanisms.  
Pergolide 
 Among DAergic agonists, the synthetic ergoline derivate 
pergolide mesylate has recently been indicated in mono-
therapy as an efficacious and well-tolerated first-line treat-
ment in patients with early stage PD. However, its clinical 
use has been limited, since it was recently shown to be 
associated with the development of restrictive valvular heart 
disease [66-68].  
 The neuroprotective effect of pergolide has been 
observed both in vivo and in vitro. Chronic administration of 
pergolide preserved the integrity of nigrostriatal neurons in 
the aging rat brain [69] and protected neurons against 
reduction of striatal DA and its metabolites after 6-OH-DA 
injection in mice [70]. Using cell culture models, pergolide 
has been shown to promote the survival of DAergic neurons, 
to exhibit partial protection against MPP
+
 toxicity and to 
increase 
3
H-DA uptake by cultured cells after levodopa 
treatment [71]. The neuroprotective effect of pergolide has 
been shown to be mediated by free radical scavenging 
activity particularly hydroxyl radicals and nitric oxide and by 
decreasing phospholipid peroxidation [72, 73] suppressing 
apoptotic pathways by inhibiting of NF-B nuclear 
translocation [74] and stabilizing the mitochondrial function 
[71]. In clinical trials pergolide was shown to reduce the 
long-term decline of striatal fluorodopa uptake compared to 
levodopa treatment, however, without reaching statistical 
significance [75]. 
 Data obtained in our laboratory demonstrated that 
pergolide protected SH-SY5Y neuroblastoma cells from cell 
death induced by H2O2 [76]. Neuroprotection was elicited 
when pergolide was added to the culture medium either 
simultaneously or before H2O2 treatment. Neuroprotection 
by pergolide was not prevented by preincubation of the cells 
with phenoxybenzamine, spiperone, SCH23390 or (-)-
sulpiride, suggesting that drug effects were not mediated by 
DA receptor stimulation. Moreover, the neuroprotective 
effect of pergolide was specific for H2O2, since doxorubicin 
or cis-platinum- induced cell death was not affected by the 
presence of the DA agonist drug in the culture medium.  
 Treatment of SH-SY5Y neuroblastoma cells with 
pergolide significantly prevented glutathione depletion [76]. 
Since oxidative stress in SH-SY5Y neural cells is known to 
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activate NF-B pathway we tested the hypothesis that 
pergolide may interfere with NF-B transcriptional activity 
[77, 78]. We showed that exposure of human SH-SY5Y neu-
ronal cell line to H2O2 results in NF-B nuclear translo-
cation, activation of p53 and p53-target genes, including p21, 
Gadd45, MSH2 and Bax, and apoptosis. The cell-permeable 
SN50 peptide, which is known to block NF-B/Rel nuclear 
translocation, prevented both H2O2-induced p53 expression 
and apoptosis. These results suggested that, in this particular 
cell model, NF-B activation is involved in the H2O2-
induced apoptosis. Similarly to the SN50 peptide, pergolide 
inhibited NF-B/Rel nuclear translocation in SH-SY5Y 
neuronal cell line exposed to H2O2; this effect resulted in the 
lack of p53 transcriptional activation and prevention of 
apoptosis [74]. 
Ropinirole 
 Ropinirole is a non-ergoline DA receptor agonist that 
exhibits a high affinity for the D2 and D3 receptor subtypes 
but little or no affinity for the D1 receptor [79, 80]. 
Symptomatically, it was reported that ropinirole was as 
effective as bromocriptine in reducing motor complications 
and decreasing levodopa dose without increasing adverse 
events including dyskinesia [81]. Also, ropinirole mono-
therapy was effective in treating resting tremor in early PD 
[82], in reducing periodic leg movements and in improving 
sleep efficiency in patients with restless leg syndrome [79, 
83]. These positive effects of ropinirole in PD are believed to 
be due to stimulation of the post-synaptic DA D2-type 
receptor [80]. In experimental models of PD, it has been 
found that ropinirole reversed the motor and behavioral 
deficits induced by MPTP in marmosets [80] and showed 
neuroprotective effect against 6-OH-DA in mice [84]. 
Activation of glutathione and glutathion-regulating enzymes 
such as glutathione peroxidase, glutathione reductase and 
glutathione transferase as well as activation of catalase and 
superoxide dismutase were principal neuroprotective 
mechanisms mediated by ropinirole [85].  
 In clinical trials ropinirole reduced the long-term decline 
of striatal fluorodopa uptake compared to levodopa therapy 
indicating a preserving effect on DAergic nerve endings [75, 
86]. Previous in vitro studies showed that ropinirole can 
promote the dierentiation and survival of DAergic neurons, 
and it can upregulate the expression and secretion of GDNF 
and BDNF [87]. Considering the potential eects of 
ropinirole on neuroprotection, it has been suggested that 
ropinirole may have an anti-apoptotic eect by interfering 
with MAP kinase and caspase-dependent pathway. 
 Recent studies showed that ropinirole has neuropro-
tective eect against rotenone-induced apoptosis in both SH-
SY5Y cells and primary mesencephalic cultures [88]. 
Exposure to rotenone significantly activated p-JNK, p-P38 
and p-c-Jun in SH-SY5Y cells. Activation of JNK and P38 
was responsible for the inhibition of the anti-apoptotic 
protein Bcl-2, and the induction of phosphorylation of c-Jun, 
a nuclear transcription factor and a known target of JNK, 
which further promotes the release of cytochrome c from the 
mitochondria to the cytoplasm and it leads to caspase-9 
activation [89-92]. Pretreatment with ropinirole inhibits p-
JNK, p-P38 and p-c-Jun expression, indicating that 
ropinirole may act at early stage of apoptosis. These effects 
appear to be mediated by neurotrophic factors GDNF and 
BDNF, since both of them were found to increase in the 
primary mesencephalic cultures after treatment with ropini-
role and pramipexole [87, 93]. The anti-apoptotic eect of 
ropinirole can be suppressed by D2 and D3 receptor 
antagonists sulpiride and nafadotride. Nafadotride exhibited 
greater eect in blocking ropinirole mediated anti-apoptosis, 
suggesting that D3 receptor may play a significant role.  
Pramipexole 
 Pramipexole, a non-ergoline DA agonist, has been 
success-fully applied to the treatment of PD. Similarly to 
ropinirole, pramipexole exhibits a high affinity for the D2 
and D3 receptor subtypes but little or no affinity for the D1 
receptor. The neuroprotective effects elicited by this drug 
have directly and/or indirectly been associated with 
antioxidant effects, mitochondrial stabilization or induction 
of the antiapoptotic Bcl-2 family. In particular, Le et al. [94] 
reported that pramipexole protected DAergic MES 23.5 cell 
line against DA, 6-OH-DA and hydrogen peroxide-induced 
cytotoxicity possibly through antioxidant effects, and such 
neuroprotection was independent from DA receptor 
stimulation not being prevented by selective D2 or D3 
antagonists. Similar results were obtained by Fujta et al., 
[95] and Uberti et al. [96], who demonstrated that prami-
pexole inhibits the generation of H2O2-induced reactive 
oxygen species in PC12 cells and SH-SY5Y neuroblastoma 
cells, respectively. 
 Because of its antioxidant properties, pramipexole has 
been proposed to be effective against other pathologies, 
beside PD, where oxidative stress is the main mechanism 
implicated in pathophysiology of the diseases. In fact, 
oxidative abnormalities have been identified both in familiar 
and sporadic amyotrophic lateral sclerosis (ALS). The 
treatment of patients affected by ALS with pramipexole 
reduced the systemic production of oxygen radicals, as 
demonstrated by measuring the levels of 2,3-dihydroxy-
benzoic acid (2,3-DHBA) in the blood, suggesting that 
pramipexole may interrupt free radical production in ALS 
[97] 
 In search for an appropriate cell model for studying 
neuroprotection, Presgraves et al. [98] characterized 
differentiation conditions of the SH-SY5Y neuroblastoma 
cell line for phenotypic markers of DAergic cells, Cells were 
differentiated with retinoic acid (RA), 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), and RA followed by TPA 
(RA/TPA). Interestingly, RA/TPA differentiated cells 
exhibited 3-fold and 6-fold higher levels, respectively, of DA 
D2 and D3 receptors than undifferentiated or RA-
differentiated cells. Pretreatment with pramipexole was 
protective against MPP
+
 in the RA/TPA differentiated cells 
but not in undifferentiated or RA differentiated cells. The 
neuroprotective effect of pramipexole was concentration-
dependent and DA D2/D3 receptor dependent. In contrast, 
protection by pramipexole against DA was not DA receptor 
dependent. This model system provides unique information 
about DA receptor dependent and independent mechanisms 
of neuroprotection. 
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Fig. (1). Schematic representation of the pharmacological properties of apomorphine (A), bromocryptine (B), pergolide (C), ropinirole (D), 
and pramipexole (E) that are responsible for putative neuroprotection and neurorestorative effects. 
 
 An additional mechanism underlying protection by 
D2/D3 receptor agonists has been suggested to involve 
neurotrophic factors. To verify this hypothesis, the D3 
receptor preferring agonists S32504 [(+)-trans-3,4,4a,5, 
6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-
1,4-oxazine] and pramipexole were utilized in a terminally 
differentiated neuroblastoma SH-SY5Y cell line exhibiting a 
DAergic phenotype [99]. The cytotoxic effects of MPP
+
 
were stereospecifically antagonized by S32504 and by 
pramipexole, but not by their inactive stereoisomers, R(+) 
pramipexole and S32601, respectively. Neuroprotective 
effects afforded by S32504 and pramipexole were speci-
fically antagonized by the selective D3 antagonists S33084, 
U99194A, and SB269652, and by the D2/D3 antagonist 
raclopride. The preferential D2 receptor antagonist 
LY741626 was ineffective as the D1 antagonist SCH23390.  
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 BDNF potently protected against MPP
+
-induced neuro-
toxicity. An antibody directed against BDNF concentration-
dependently blocked both the neuroprotective effects of 
BDNF and those of pramipexole and S32504 against MPP
+
. 
The protection afforded by BDNF was blocked by the PI3K-
AKT pathway inhibitor LY249002. Neuroprotective effects 
of pramipexole and S32504 against MPP(+) toxicity appear 
to be mediated by D3 receptors stimulation. Their actions 
also reflect downstream recruitment of BDNF via a PI3K-
AKT pathway. 
 An increasing amount of evidences suggest a central role 
of oxidative stress also in AD pathogenesis [100, 101]. 
Furthermore, many findings link free radical formation with 
excessive A deposition [102-105]. A is a 39-43 amino 
acid long peptide derived from the amyloidogenic processing 
of the larger amyloid precursor protein [106, 107]. The basic 
hypothesis in AD has been that enzymatic cleavage of the 
amyloid precursor protein generates the release of monomers 
of A, that undergo conformational changes concomitant 
with self assembly into oligomers and then fibrils. During 
the fibril formation process, the peptides acquire neurode-
generative properties. The ability of toxic A  peptides to 
induce protein oxidation and inhibit the activity of oxidation-
sensitive enzymes is consistent with the hypothesis that A 
can act like a pro-oxidant agent [103, 108]. We recently 
studied the role of free radical in the neurotoxic events 
caused by different A aggregation states, and investigated 
the neuroprotective effects of pramipexole in neuronal death 
induced by unaggregated, oligomeric and fibrillary A 
species [96]. Increasing evidences are now available sug-
gesting that protofibrillar aggregates of A recognized as 
diffuse plaques by neuropathological examination, are 
indeed the most toxic A species. Oligomers of A, rather 
than monomers or large fibrils, may form pores in the cell 
membrane, allowing influx of ions, that disrupt neuronal 
signalling and initiate cell death cascade [109, 110]. These 
data strongly support the hypothesis that each of the A 
aggregation state possesses different biological and patho-
logical functions We challenged the neuronal SH-SY5Y cell 
line with A1-42 peptide in different states of aggregation. 
Contrary to unaggregated peptide, oligomers and fibrils 
caused generation of ROS and this effect was inhibited by 
pramipexole in a DA receptor independent manner. The 
interaction of pramipexole with A activity is further 
supported by the data showing that pramipexole prevented 
the induction of caspase 3 activated by A25-35 [111].  
3. PERSPECTIVES 
Neuroimaging Studies in PD Patients 
 To evaluate the possibility that DA agonists may indeed 
prevent DAergic cell loss a number of recent clinical studies 
compared rates of DA neuron degeneration after treatment 
with ropinirole, pramipexole, or levodopa by means of 
neuroimaging techniques [86, 112]. These trials included 
neuroimaging substudies to analyze for possible neuro-
protection by DA agonists. The CALM-PD study used -CIT 
SPECT scanning techniques at baseline and month 23 in 82 
patients [113, 114]. The mean change per year of CIT uptake 
was similar for both treatment groups. In the ropinirole study 
28 ropinirole-treated patients and 9 levodopa-treated patients 
were evaluated. A trend was seen toward preservation of 
DAergic function in the striatum in the ropinirole group, 
especially in those patients who had the disease for less than 
two years. A similar trend was found in the pergolide trial 
using PET studies [115].  
 Radiotracer imaging of the nigrostriatal DAergic
 
system 
is a widely used but controversial biomarker in PD. 
Biomarkers used to study disease biology rely on evidence 
that
 
they are measuring relevant biologic processes. The four 
radiotracers
 
used as biomarkers in PD, namely [
18
F] 
fluorodopa PET, (+)-[
11
C]dihydrotetrabenazine
 
PET, [
123
I]-
CIT SPECT, and [
18
F]fluorodeoxyglucose
 
PET, fulfil this 
criterion, although they do not measure the number
 
or 
density of DAergic neurons. Biomarkers used as diagnostic
 
tests, prognostic tools, or surrogate endpoints must not only
 
have biologic relevance but also a strong linkage to the 
clinical
 
outcome of interest. No radiotracers fulfil these 
criteria,
 
and current evidence does not support the use of 
imaging as
 
a diagnostic tool in clinical practice or as a 
surrogate endpoint
 
in clinical trials [116, 117].  
Dopamine Agonists and Dementia 
 Prevalence of dementia in community-based PD cohorts 
is between 20% and 40%. The development of dementia in 
PD is associated with a twofold increased mortality, reduced 
quality of life, increased caregiver distress, and nursing 
home placement. Dementia also limits the drug treatment of 
extrapyramidal motor impairments, because L-DOPA may 
exacerbate psychotic features and confusion [2, 118, 119]. 
 From a neuropathological and neurochemical point of 
view, cholinergic deficits are more marked in PD patients 
with dementia compared to those without, as evidenced by 
greater neuronal loss in the nucleus basalis of Meynert. 
Furthermore, by using a ligand of vesicular acetylcholine 
transporter, PDD cases demonstrate extensive cortical 
binding decrease similar to AD. In PDD, extrastriatal 
DAergic and particularly cholinergic deficits appear to play a 
central role in mediating dementia. Management of dementia 
in PD represents one of the major therapeutic challenges. 
Still, it is not yet well established if cognitive impairment is 
part of PD or the clinical manifestation of an independent, 
concomitant neurodegenerative disease [118-119]. Despite 
this unsolved question, we propose that DAergic drugs may 
be useful in delaying the progression of the neurode-
generative processes. In fact, independently from the 
etiopatogenesis of the specific neurodegenerative disease 
that is responsible for the cognitive impairment, they share 
common deleterious processes, i.e. neuronal loss and protein 
aggregation. In this regard, it should be noted that DA 
agonists were found to be active in preventing A  
aggregation and ROS formation [22-25, 96]. 
 A large body of recent data indicates considerable 
heterogeneity between different neurodegenerative diseases, 
including AD, PD, PDD, and LBD. Many of the clinical 
syndromes and pathologies overlap, and, due to molecular 
interaction between various proteins, many phenotypes show 
mixed neuropathologies. Only few are featured by one single 
principal pathology with no or only minimal additional 
lesions. Diagnosis is thus hampered by the onset of the main 
neurological symptom and it is often unchanged by the 
occurrence of delayed clinical manifestations. In this regard, 
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several clinical and epidemiological studies linking vascular 
factors to the pathogenesis of AD strongly argue that the 
large majority of sporadic AD patients show a so-called 
“mixed dementia” characterized by neurodegenerative and 
vascular lesions typical of both AD and vascular dementia 
[120-122]. 
4. CONCLUSION 
 The mechanism of action of different DA agonists 
currently used for the treatment of PD patients does not 
appear to be entirely restricted to the restoration of the 
decreased striatal DA input through the stimulation of 
selective DA receptor subtypes. These drugs are endowed 
with intrinsic and peculiar antioxidant, antiapoptotic, neuro-
trophic and anti-fibril formation effects. These activities are 
molecule-specific and may represent additional pharma-
cological properties contributing to their clinical efficacy in 
PD.  
 In conclusion, since the independent and synergistic 
multi-sites of action, we propose selective DA agonist drugs 
as coadiuvants in the treatment of chronic and progressive 
neurodegenerative diseases in which oxidative injury and/or 
protein misfolding and aggregation exert a primary role. 
However, the molecular evidence suggesting additional 
pharmacological properties of the DAergic drugs deserve 
further clinical studies to determine if these drugs can indeed 
slow down the neurodegenerative disease progression. 
ACKNOWLEDGEMENT 
 This work was supported by PRIN 2005 grants from the 
Italian Ministry of Education, University and Research 
(project numbers 2005054147_005 and 2005054147_001). 
ABBREVIATIONS 
6-OH-DA = 6-Hydroxydopamine 
AAV2 = Adeno-associated virus type 2 
A = -Amyloid peptide 
BDNF = Brain derived neurotrophic factor 
COMT = Cathecol-O-methyl transferase 
DA = Dopamine 
DOPA = 3,4-Dihydroxyphenylalanine 
GDNF = Glial derived neurothophic factor 
LBD = Lewy bodies dementia  
MPP = 1-Methyl-4-phenylpyridinium 
MPTP = 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine 
PD = Parkinson’s disease 
PDD = Parkinson's disease with dementia 
PI3K = Phosphatidylinositol 3 kinase 
RA = Retinoic acid 
ROS = Radical oxygen species 
SNpc = Substantia nigra pars compacta 
SVZ = Subventricular zone 
TPA = 12-O-Tetradecanoyl-phorbol-13-acetate 
-CIT = [123I]2-Carbomethoxy-3(4iodophenil) 
tropane 
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